Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A Phase II Study of Pembrolizumab in Subjects with Triple-Negative Breast Cancer
(1) Objective (Cohorts A+C): To evaluate the Overall Response Rate (ORR) to pembrolizumab as 2L+ monotherapy in subjects with PD-L1 strong (+) centrally confirmed mTNBC, based on RECIST 1.1 as assesse...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Merck Sharp & Dohme (MSD)
Update Il y a 4 ans
Étude NCT03515837 : étude de phase 3 évaluant l'efficacité et la sécurité du pémétrexed associé à une chimiothérapie à base de sel de platine et associé à du pembrolizumab chez des patients ayant un cancer du poumon non à petites cellules métastasique avec une mutation de type EGFR résistant à un inhibiteur de la tyrosine kinase. [Informations issues du site clinicaltrials.gov et traduites par l'INCa]
Le cancer du poumon se développe à partir de cellules situées dans le poumon qui se sont multipliées de manière anormale pour former une tumeur. Le cancer du poumon non à petites cellules représente 8...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Immunothérapie - Vaccinothérapie
,
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
NovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc)
Update Il y a 4 ans
A multicentre, randomized, double-blind, placebo controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms, diuresis, renal function, and clinical outcomes in subjects hospitalized with worsening renal function and heart failure requiring intravenous therapy
The main objective of this study is to evaluate the effect of KW-3902 IV, in addition to standard therapy, on the proportion of worsening heart failure and worsening renal function after initiation of...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
To compare overall survival (OS) time by treatment arm.
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) in the Treatment of Men with Osteoporosis Treated with Vitamin D and Calcium 1
2.1.1 Primary (1) Objective: To assess the effect of odanacatib 50 mg once weekly versus placebo on lumbar spine BMD over 24 months. 2) Objective: To assess the safety and tolerability of odanacatib...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme GesmbH
Update Il y a 4 ans
Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy Children
Main objective : (1) To evaluate the immunogenicity of intramuscular INFANRIX™ hexa (in relation to serum anti-polyribosylribitol phosphate [PRP] and anti-hepatitis B surface antigen [HBsAg]) when adm...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Study to test the safety, tolerability, and effectiveness of sitagliptin when compared to placebo in reducing the amount of insulin (with or without metformin) needed per day, to control blood sugar, over a 24-week period
After 24 weeks, to assess the effect of sitagliptin compared with placebo on the change in insulin dose in IU per day in patients with type 2 diabetes mellitus (T2DM) with inadequate glycemic control ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
A Phase II Randomised, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK 7009 when administered concomitantly with Pegylated Interferon and Ribavirin in treatment- naive patients with chronic genotype I Hepatitis C Virus Infection
To evaluate the antiviral activity of the MK-7009 b.i.d. treatment regimens with 24 weeks of total duration (treatment regimens 1 to 4) as compared with placebo in combination with 48 weeks of peg-IFN...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp and Dohme de España
Update Il y a 4 ans
A prospective, multicenter, randomized, double-blind, pilot study to evaluate the safety, the efficacy, the tolerability, and the emergence of resistant gram-negative microorganisms in the bowel in elderly patients with serious community-acquired bacterial pneumonia treated with a short regimen fo ertapenem versus high-dose levofloxacin
a. In elderly patients (≥ 65 years old) who are clinically evaluable, to assess the efficacy of ertapenem with respect to high-dose levofloxacin measured as the proportion of patients achieving a favo...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Merck, Sharp & Dohme Ireland (Human Health) Limited
Update Il y a 4 ans
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of L-000796568 in Postmenopausal Women With Overactive Bladder
In postmenopausal women with overactive bladder: (1) To investigate a dose-related reduction, in average number of daily micturitions after 8 weeks of treatment with L 000796568 (375, 125, or 50 mg on...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
4
5
6
7
8
9
10
11
12
13
Next